drugset / Trial / NCT05121714
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Non-randomizedCrossoverOpen-labelPrevention
Summary
A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs
Timeline
- Start
- 2020-12-17
- Primary completion
- 2021-05-18
- Completion
- 2021-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | 50 mg | Oral |
| Subject | Fluvoxamine | Unknown | 100 mg | — |
| Subject | Obefazimod | Small molecule | 50 mg | Oral |
Indications
No indication recorded.